KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Exact Sciences (EXAS) Revenue (2016 - 2025)

Exact Sciences has reported Revenue over the past 16 years, most recently at $878.4 million for Q4 2025.

  • Quarterly Revenue rose 23.12% to $878.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 billion through Dec 2025, up 17.69% year-over-year, with the annual reading at $3.2 billion for FY2025, 17.69% up from the prior year.
  • Revenue was $878.4 million for Q4 2025 at Exact Sciences, up from $850.7 million in the prior quarter.
  • Over five years, Revenue peaked at $878.4 million in Q4 2025 and troughed at $402.1 million in Q1 2021.
  • The 5-year median for Revenue is $625.2 million (2023), against an average of $617.8 million.
  • The largest YoY upside for Revenue was 61.72% in 2021 against a maximum downside of 1.6% in 2021.
  • A 5-year view of Revenue shows it stood at $473.8 million in 2021, then grew by 16.71% to $553.0 million in 2022, then grew by 16.98% to $646.9 million in 2023, then grew by 10.29% to $713.4 million in 2024, then increased by 23.12% to $878.4 million in 2025.
  • Per Business Quant, the three most recent readings for EXAS's Revenue are $878.4 million (Q4 2025), $850.7 million (Q3 2025), and $811.1 million (Q2 2025).